EDITOR'S DESK

  • 4 Takeaways From The World Biosimilar Congress
    4 Takeaways From The World Biosimilar Congress

    Throughout this whirlwind two-day event, the panelists addressed the challenges of patient education and uptake, the pharmacovigilance of biosimilars, and how to navigate varying regulatory requirements in the global market. But there were four key messages relayed throughout this conference that are worth noting.

Navigating Brazil’s Emerging Biosimilar Market

The Latin American markets, and especially Brazil, hold great promise for biosimilar development, PlantForm CEO Don Stewart says. In recent years, many partnerships have been launched in Brazil between local and international companies to bolster the country’s biosimilar development. However, there are a number of things companies looking to forge joint ventures in Brazil need to keep in mind for success.

Some Biopharma Haven’t Caught Outsourcing Enthusiasm

I often write – and you read – about those individuals at biopharma companies openly enthusiastic about outsourcing. Not too long ago, though, I ran into a person who seemed to outdo the others in absolute embrace of this model. But here’s the catch: Her company won’t allow her enthusiasm to be shared “on the record.”

“Growing” Biosimilars: How Plants Bolster Manufacturing Efficiency

Roughly 15 to 20 years ago, a number of pharmaceutical companies raised money to employ tobacco technology in drug development. Unfortunately, this rush did not lead to the success many were hoping for. However, the successes of recent players in this space suggest pharma could be entering a new age in plant-based manufacturing.

Will Medicare Part D Make Biosimilar Manufacturers Pay?

Despite biosimilars’ reputation as cheaper alternatives to costly biologics, Medicare Part D patients likely won’t see great savings at least not right away. According to a recent Avelare Health report, there are two ways patients could see reduced biosimilar out-of-pocket costs. But one of these solutions could place a big burden on biosimilar manufacturers. 

More From Editor's Desk

GUEST CONTRIBUTORS

More From Guest Contributors...

BIOPROCESSING WHITE PAPERS

Dangerous Goods Classification Confusion: UN 3373 Biological Substance, Category B

In the previous blog post “Infectious Biologicals Category A and B - Classification Guidelines,” I provided definitions of Infectious Biologicals Category A and B and some basic guidelines on how to classify your shipments. These definitions are clear and helpful when you know that your shipment contains pathogens. In that case, it is either on the list for Category A, or if it is not, then it is classified as Category B. By Michael Gotz

Real-Time Particle Sizing For Granulation Control

Across the pharmaceutical, food and chemical industries, granulation processes are used to convert light, fine powders into larger, more dense granules, to make fast-dissolving drinks, optimized blends for compression tableting and granules for waste water absorption applications, for example. Also in the manufacture of catalysts.

More White Papers...

BIO INDUSTRY POSTERS

More Bioprocessing Posters...

ON-DEMAND WEBINARS

More Webinars On-Demand...